South East Health, Biotech & Nutrition R&D Companies Directory

Vaccines Manufacturing and Innovation Centre UK Ltd was established as a strategic national infrastructure project to bolster the UK's capability in vaccine development and large-scale manufacturing. The organisation focuses on providing the facilities and technical expertise required to accelerate the transition of vaccine candidates from research to commercial production. Its work has centred on building and operationalising a specialised centre to ensure national resilience in biopharmaceutical manufacturing.

GlaxoSmithKline (GSK) is a global biopharmaceutical company focused on the research, development, and manufacture of innovative medicines and vaccines. Their R&D strategy leverages advanced digital technologies, including artificial intelligence, machine learning, and genomic sequencing, to accelerate drug discovery and optimise manufacturing processes. The company frequently collaborates with academic institutions, NHS trusts, and technology partners to address complex healthcare challenges such as neurodegenerative diseases, infectious threats, and personalised medicine.

The University of Surrey is a leading UK research institution that bridges the gap between fundamental academic inquiry and industrial application. Their work spans diverse domains including advanced telecommunications, sustainable food systems, AI-driven data marketplaces, and aerospace manufacturing. By leveraging a broad network of industry partners, they translate complex scientific research into practical solutions for societal and economic challenges.

Oxford Biomedica is a global leader in the development and manufacture of lentiviral vectors, providing essential platform technologies for cell and gene therapies. Their work spans the entire value chain from clinical development to commercial-scale GMP manufacturing, with a focus on integrating advanced robotics, digital frameworks, and process analytical technologies. The company has evolved from a pioneer in in vivo delivery to a large-scale manufacturer supporting major commercial products like Kymriah.

Oxford Expression Technologies is a biotechnology company specialising in the development of vaccines using insect cell expression systems, particularly the flashBAC platform. Their work focuses on creating affordable vaccines for neglected epidemic diseases such as Crimean-Congo haemorrhagic fever and COVID-19, targeting low- and middle-income countries. The company has evolved from early research on CCHF to COVID-19 vaccine development and back to advancing CCHF vaccines into clinical studies.

The University of Reading is a leading UK research institution that leverages its academic expertise to drive industrial innovation through Knowledge Transfer Partnerships (KTPs) and collaborative R&D. Their work spans diverse sectors including MedTech, sustainable agriculture, energy systems, and behavioural finance, focusing on translating complex research into practical commercial applications. By partnering with SMEs and large enterprises, the university facilitates the adoption of advanced technologies such as machine learning, data analytics, and smart materials to solve real-world operational and environmental challenges.

iosBio (formerly Stabilitech) is a biotechnology company specialising in thermostable oral vaccine delivery. They have developed a proprietary stabilisation platform that protects fragile biologics such as viral vectors and mRNA-LNPs, enabling oral administration without cold chain logistics. Their work spans global epidemic preparedness, agricultural bacteriophage formulations, and next-generation mRNA vaccine stability.

The University of Oxford is a world-leading academic institution that conducts high-impact translational research in medical science and public health. Their work focuses on the development and clinical validation of innovative vaccines to address global health challenges, specifically targeting vector-borne diseases. They leverage extensive research capabilities to advance clinical trials for complex, multivalent prophylactic solutions.

Camallergy is a biotechnology company developing a novel oral immunotherapy drug, CA002, for the treatment of peanut allergy. Their treatment desensitises patients through gradual exposure to allergenic proteins, aiming to provide protection within 12 weeks. Having demonstrated >95% success in an early access programme, they are now conducting Phase 3 clinical trials in the UK and Ireland to support regulatory approval.

Kymira is a UK-based e-textile company that develops smart garments with embedded sensors and energy harvesting for sports and medical applications. Starting with performance sportswear, the company has evolved to create wearable platforms for fetal health monitoring, cardiovascular diagnostics, and musculoskeletal rehabilitation, leveraging its proprietary textile technology.

Theolytics is a biopharmaceutical company developing oncolytic virus therapies for hard-to-treat cancers, focusing on ovarian cancer and multiple myeloma. Their work has progressed from early platform development for arming oncolytic viruses to preclinical validation and now a phase 1 clinical trial for platinum-resistant ovarian cancer. The company collaborates with the University of Sheffield and leads all its grant-funded projects.

Oxular is a UK-based retinal therapeutics company developing a novel ocular drug delivery device and drug product for the treatment of ocular cancers such as retinoblastoma and uveal melanoma. Their technology enables precise, minimally invasive local drug delivery to the eye, aiming to reduce patient trauma and improve outcomes over systemic treatments. The company has progressed from early feasibility studies to clinical validation across multiple Innovate UK grants.

Infinitopes is a Cancer Research UK-led spinout from Oxford University developing antigen-specific minigene vaccines to prevent cancer metastases. Their technology combines accurate tumour target identification with high-efficiency delivery to durably stimulate patients' immunity. Their work has evolved from preclinical minigene vaccine development for oesophageal cancer to a precision immunomics platform progressing into a human clinical trial.

OrthoSon is a medtech company developing minimally invasive solutions for spinal disc repair, focusing on a needle-based procedure to restore intervertebral disc function without major surgery. Their technology includes a nucleus augmentation device and a preformed biomaterial plug (SAFR) for annulus fibrosus repair, with preclinical testing at Imperial College London. They have evolved from feasibility studies to collaborative R&D for a biomaterial implant.

SynaptixBio is a UK-based rare disease biotech SME pioneering antisense oligonucleotide (ASO) therapeutics for TUBB4A-related leukodystrophies, a group of neurodegenerative diseases with no existing treatments. Their work spans from drug development to first-in-human clinical trials, targeting paediatric and adult forms of the disease.

Mana Biosystems develops insect bioconversion technologies using Black Soldier Fly larvae to convert organic waste into sustainable protein for animal feed. Their work spans circular economy waste mapping in East Africa, modular insect farms, AI-enhanced monitoring systems, and nanomaterial biofortification to improve insect meal economics.

VisusNano is a medtech start-up developing a drug-eluting intraocular lens (MEDILens) for cataract surgery, designed to eliminate the need for postoperative eye drops. The company's technology combines biodegradable polymers with sustained drug release to reduce inflammation and improve patient outcomes. Over four grants, VisusNano has progressed from feasibility studies to expanding the lens platform for glaucoma management, targeting both human and veterinary markets.

Sense Biodetection develops single-use, handheld molecular diagnostic tests for infectious diseases and cancer screening. Their technology combines the accuracy of lab-based molecular testing with the speed and ease of use of rapid tests. They have evolved from early feasibility projects to late-stage development of an instrument-free molecular test for influenza and RSV.

The Pirbright Institute is a world-leading centre of excellence in the study of viral diseases of livestock and viruses that spread from animals to humans. Their work focuses on the development of innovative vaccines and rapid diagnostic tools to mitigate the impact of zoonotic pathogens on both animal health and global food security. Through strategic collaborations, they translate fundamental virological research into practical, field-ready solutions for disease control.

IS-Instruments develops advanced Raman spectroscopy instruments for industrial and medical applications. Their technology combines photonic sensing with machine learning and robotics for gas monitoring, biopharmaceutical process analytics, and environmental detection. The company's grant history shows evolution from early feasibility studies to commercial-scale collaborative projects in healthcare and clean energy.